We thank Aghaji et al 1 for their interest in our article. 2 We would like to point out, however, that this letter is discussing an entirely separate issue, namely, the need to improve the access to care for children with cataract worldwide, especially in underprivileged areas. Our paper is a quality assurance study driven by factors imposed in a developed country in which patients and payers expect to see quality outcome reports that may be reflective of the surgical and institutional quality of service. In this study, we utilized exclusion criteria that would eliminate confounding factors that might impact visual acuity outcomes. One example is the exclusion of children with congenital cataract who had significant delays in presentation, since the visual outcomes would not be reflective of the surgical care provided, but, rather, the result of irreversible deprivation amblyopia. By eliminating as many confounding factors as possible, it allowed us to examine outcomes that are more directly influenced by quality of care. Our study is like adult benchmark papers that report only on populations with 'uncomplicated' acquired cataract. In contrast, the patients that are reported in the letter represent children who would be expected to have poor visual outcome by common standards, because of the late presentation, even though quality of the surgical care was good. As the authors point out, the outcomes are biased because the study population consists of children with cataract who were enrolled in a school for the blind. There is no information in the letter about quality of surgical care or quality assurance in general. The population and outcomes are similar to those reported by Ganesh et al. 3 While we appreciate and support the thoughts in this correspondence, it must be clear that the purpose of our paper, which reports quality assurance results with timely intervention and modern techniques, is different from the outcomes that might be found for children with more complex conditions or delayed interventions. Surgery for these children may still provide improved visual function, but the final vision is understandably less good than in our study, and the issue is not the quality of care at the time of surgery. The issue is need for improved surveillance and timely intervention in underserved areas. We support increased awareness of the need for better global pediatric eye care particularly with regard to diagnoses outlined in the WHO 2020 bulletin, which includes treatment of children with early childhood cataract. 4 
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The authors declare no conflict of interest. Recent evidence-based guidelines recommend continuation of anticoagulants in patients undergoing cataract surgery provided that the international normalized ratio is in the therapeutic range and that aspirin be discontinued perioperatively only if the risk of bleeding outweighs its potential benefit. 3 Although the 2009 meta-analysis found that, patients taking warfarin while undergoing cataract surgery had a three-fold increase of bleeding events compared to those not on warfarin, but the vast majority of bleeding events were self-limited, typically hyphemae or subconjunctival hemorrhage. 4 There was no evidence that continuing warfarin had a negative impact on postoperative visual acuity. Recent meta-analysis, including seventeen randomized controlled studies, reported no differences in the risk of substantial intraocular bleeding (that is, hyphema, vitreous hemorrhage, subretinal hemorrhage, and suprachoridal hemorrhage) between NOAs and other antithrombotic drugs. 5 In summary, several studies show a higher incidence of subconjunctival hemorrhage in patients undergoing cataract surgery while taking antiplatelet or anticoagulant medication, but the available data do not show an increase in sight-threatening complications or decreased postoperative visual acuity. Sir, Searching for the best blood-derived eye drops
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A Grzybowski
We have read with great interest the article by Than et al 1 regarding the use of fingerprick autologous blood (FAB) as an alternative treatment for dry eye syndrome (DES). Sixteen patients diagnosed with DES were treated with FAB, 11 of whom had Sjögren syndrome, obtaining good results for the different clinical variables evaluated. The treatment dosage was four times daily for eight weeks. We commend the authors' search of a low-cost and readily accessible treatment for this type of syndrome. At the same time, we would like to offer some commentaries and additional perspectives to the study. 1 First, our experience is that, in order to achieve optimal therapeutic effects, it would be recommended that the concentrations of platelets and growth factors would be greater than those obtained in whole blood. A good example of that is platelet-rich plasma (PRP), 2 a therapy in which platelets are concentrated in a volume of plasma. Furthermore, we speculate that if platelet activation is not completed in FAB, the amount of platelet-derived growth factors would be lower than even autologous serum (AS).
Second, the authors should clarify whether there is platelet activation in the ocular surface, or whether it does not always occur, for example due to the clearance of FAB. The authors state that clots are observed in some patients, but this should be generalized so that the method is reproducible. Recent studies carried out on ocular surface cells show that the biological activity of non-activated PRP is lower than AS or other activated PRPs, such as plasma rich in growth factors (PRGF). 3 Third, it is important to highlight that most of the patients (11/16) had been diagnosed with Sjögren syndrome, a long-term autoimmune disease in which the already exacerbated inflammatory component of DES is accentuated. 4 An interesting approach for these cases might be to perform an inactivation protocol of immune components in the eye drops, preserving most of the biologically active molecules while reducing immunoglobulin content and complement activity. 5 Last but not least, there are other issues to be considered, including the drawback of not using a standardized ready-to-use product, the large amount of fingerpricks delivered (448 fingerpricks in 8 weeks), and the variability of capillary blood. 6 We strongly encourage the authors to further deepen research in the FAB mechanisms of action and product composition in order to optimize the treatment and improve the quality of life of DES patients, thus offering a fully characterized product.
